Clinical Trial

LBL-2016 for Children or Adolescents in China

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The outcomes of children with lymphoblastic lymphoma (LBL) in China in the investigators' previous study were not unexpected. In this study, through further modification treatment protocols and strengthen domestic multicenter collaboration, the investigators try to improve survival for children with LBL when compared to the previous study.
Protocol Amendment History 12 amendments
This ClinicalTrials.gov record has been amended 12 times since 2016-07-24; most recent amendment 2026-03-17.
Status change: Recruiting → Active, Not Recruiting 2022-03-17
Trial Details
NCT Number NCT02845882
Lead Sponsor Children's Cancer Group, China
Collaborators: Shanghai Children's Medical Center, Tongji Hospital, West China Second University Hospital, Qilu Hospital of Shandong University, Tianjin Medical University Cancer Institute and Hospital, Children's Hospital of Soochow University, Nanjing Children's Hospital, Xiangya Hospital of Central South University
Conditions Lymphoblastic Lymphoma
Enrollment 150 participants
Start Date 2016-01
Primary Completion 2023-12-31 (estimated)
Study Completion 2031-12 (estimated)
Updated on ClinicalTrials.gov 2026-03-18